Citigroup
SXTP icon

Citigroup’s 60 Degrees Pharmaceuticals SXTP Stock Holding History

Citigroup’s Portfolio SXTP Stock Details SXTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2 Buy
+1
New +$3 ﹤0.01% 5836
2025
Q4 		– Sell
-47
Closed -$278 – 6464
2025
Q3 		$278 Buy
+47
New +$286 ﹤0.01% 5746

Other funds holding SXTP

KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TPWA
Twin Peaks Wealth Advisors Burlingame, California $397M AUM 23.23% 1-Year Est. Return

Citigroup's SXTP Position: Q1 2026 in Review

Citigroup opened a new position in 60 Degrees Pharmaceuticals (SXTP) in Q1 2026: 1 share worth $2. The stake represents ﹤0.01% of the portfolio and ranks #5836 among its holdings. This is a return to the name: Citigroup previously reported a position in SXTP as recently as Q3 2025.

Citigroup first reported a position in SXTP in Q3 2025 and has held it in 2 quarters since. The position peaked at $278 in Q3 2025. 8 funds tracked by Wall St. Rank hold SXTP as of Q1 2026.

  • Citigroup held 1 share of 60 Degrees Pharmaceuticals worth $2 as of Q1 2026.
  • 60 Degrees Pharmaceuticals was a new Citigroup position in Q1 2026.
  • 60 Degrees Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5836 holding.
  • Citigroup first reported a position in 60 Degrees Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • Citigroup's 60 Degrees Pharmaceuticals position peaked at $278 in Q3 2025.
  • 8 funds tracked by Wall St. Rank held 60 Degrees Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.